England Faces Unprecedented Medication Shortages, Pharmacies Operating at Significant Losses
Patients across England are confronting a severe and worsening scarcity of vital medications. Hundreds of everyday drugs, crucial for conditions ranging from epilepsy to Parkinson's disease, are now exceptionally challenging to procure. This situation is compelling individuals like Chloe, 29, to endure prolonged searches for Lamotrigine-based medication to manage her epilepsy, with recent lapses in supply leading to seizures and injuries.
The current fragility in medication access is attributed to a combination of escalating global prices and a structural flaw within the UK's medicine funding mechanism. The NHS operates a fixed-price reimbursement model for pharmacies, which has become unsustainable as wholesale drug costs frequently exceed the amount pharmacies are paid. While a 'price concessions list' exists to adjust reimbursement for rising costs, its response is often too slow, leaving pharmacies to absorb significant losses. In April, this list reached a record high of 210 named medications.
Pharmacist Akash Patel in Shepperton, Surrey, highlighted the operational strain, detailing how his pharmacy incurred a nearly GBP#9 loss on a single epilepsy prescription this month due to unreimbursed costs. To mitigate financial damage, pharmacies often stock these loss-making items at lower levels, exacerbating patient shortages. Since 2017, England has seen 1,500 High Street pharmacy closures, with 27 ceasing operations this year, bringing the total number of pharmacies to its lowest in two decades.
The underlying causes include global tensions driving up energy and transport costs, impacting medicine manufacturing which relies heavily on oil-derived ingredients. Furthermore, some manufacturers argue that persistently low UK pricing renders distribution unprofitable, prioritising sales to markets with higher returns. Experts, including Dr Leyla Hannbeck of the Independent Pharmacies Association, contend that without systemic reform, including higher overall medicine payments, the supply crisis will continue to endanger patients and the viability of community pharmacies.
